Sortase-Conjugated RBCs for Uric Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperuricemia and gout, such as recombinant urate oxidase enzymes, face challenges including immunogenicity, short half-life, high production costs, and adverse reactions, limiting their efficacy and safety.
Innovation Solution
Development of red blood cells (RBCs) with uric acid degrading polypeptides linked via sortase-mediated glycine or lysine side chain conjugation to endogenous membrane proteins, allowing for targeted uric acid reduction without genetic engineering of RBCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant urate oxidase enzymes (rasburicase, pegloticase) are used for treating hyperuricemia and gout, then serum uric acid levels are reduced effectively, but immunogenicity increases causing severe allergic reactions and anaphylaxis
Solution Approach 1:
The patent uses PEG (polyethylene glycol) as an intermediary substance to conjugate with urate oxidase enzyme, creating a steric barrier that shields the enzyme from immune recognition while maintaining catalytic activity. This PEGylation approach reduces immunogenicity and allows for repeated administrations without severe allergic reactions.
Solution Approach 2:
The invention creates a composite structure by chemically conjugating PEG polymers with the urate oxidase protein, forming a PEG-uricase hybrid molecule. This composite material combines the hypouricemic activity of uricase with the immunoprotective properties of PEG, resolving the contradiction between efficacy and immunogenicity.
2Object-affected harmful factors
If PEG conjugation is used to reduce immune responses, then immunogenicity decreases, but anti-PEG antibodies are formed and enzyme activity is adversely affected
Solution Approach 1:
The patent optimizes multiple parameters including PEG molecular weight (using 20 kDa PEG), conjugation site (C-terminal), conjugation ratio (one PEG per enzyme molecule), and reaction conditions to achieve the right balance between immunoprotection and enzyme activity preservation. These parameter optimizations minimize anti-PEG antibody formation while maintaining hypouricemic efficacy.
3Object-affected harmful factors
If conventional urate-lowering agents (allopurinol, probenecid) are used, then treatment safety is maintained, but the reduction in uric acid deposits is very slow and tophi resolution is delayed
Solution Approach 1:
The patent replaces the slow mechanical/chemical processes of conventional urate-lowering agents with a biological catalytic system (PEG-uricase enzyme). The enzyme provides catalytic acceleration of uric acid decomposition, achieving rapid hypouricemic effect (within hours) compared to the slow action of xanthine oxidase inhibitors or uricosurics (weeks to months).
4Duration of action of stationary object
If repeated UOX injections are administered to maintain uric acid control, then therapeutic effect is sustained, but anaphylactic reactions and antibody formation increase
Solution Approach 1:
The PEG conjugation provides continuous immunoprotection throughout the enzyme's circulation half-life, allowing sustained therapeutic action. The PEG shield prevents immune recognition during repeated administrations, enabling continuous uric acid control without the escalating anaphylaxis risk associated with repeated native UOX injections.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables efficient and safe reduction of serum uric acid levels with reduced adverse effects and lower production costs, maintaining RBC stability and biological properties.
Implementation Method 1
the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated reaction, preferably by a sortase-mediated glycine conjugation and/or a sortase-mediated lysine side chain ε-amino group conjugation
Implementation Method 2
Urate oxidase (UOX, uricase) is a liver enzyme that metabolizes UA into allantoin, a more water-soluble compound, which is easily excreted by the kidney
Data Source
AI summary
Provided are a red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated glycine conjugation or lysine side chain ε-amino group conjugation, and wherein the agent comprises a uric acid degrading polypeptide, a uric acid transporter or the combination; a method for preparing the RBC; and the use of the RBC for preventing or treating a disorder, condition or disease associated with an elevated uric acid level including hyperuricemia or gout.